Stock Events

Stock Events

Oxford Biomedica 

€6.4
0
+€0+0% Friday 15:47

Statistics

Day High
6.65
Day Low
6.4
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26MarExpected
Q4 2025
-0.09
-0.08
-0.07
-0.06
Expected EPS
-0.09267679795199998
Actual EPS
-0.06302956032

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OXOA.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on gene therapy products for rare diseases, directly competing with Oxford Biomedica's gene therapy solutions.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics works on genomic medicine, including gene therapy, competing in the same advanced therapy medicinal products (ATMPs) space as Oxford Biomedica.
Pfizer
PFE
Mkt Cap161.09B
Pfizer, through its acquisition of Bamboo Therapeutics and Spark Therapeutics, has expanded into gene therapy, making it a competitor in the same market as Oxford Biomedica.
Novartis
NVS
Mkt Cap297.32B
Novartis, with its acquisition of AveXis, competes in the gene therapy market, particularly in treatments for spinal muscular atrophy, a direct competition to Oxford Biomedica's offerings.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space, which is closely related to Oxford Biomedica's viral vector development for gene therapy.
uniQure N.V.
QURE
Mkt Cap1.07B
uniQure is involved in developing gene therapies for hemophilia and other genetic diseases, competing in the same therapeutic areas as Oxford Biomedica.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO is a biotechnology company specializing in the development of gene therapy products, using its NAV Technology Platform that competes with Oxford Biomedica's LentiVector platform.

About

Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary "plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.
Show more...
CEO
Dr. Frank Mathias
Employees
977
Country
United Kingdom
ISIN
GB00BDFBVT43

Listings

STU
DE
OXOA.STU
LSE
GB
OXB.LSE
MU
DE
OXOA.MU
OTC Link
US
OXBDF

0 Comments

Share your thoughts

FAQ

What is Oxford Biomedica stock price today?▼
The current price of OXOA.STU is €6.4 EUR — it has increased by +0% in the past 24 hours. Watch Oxford Biomedica stock price performance more closely on the chart.
What is Oxford Biomedica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oxford Biomedica stocks are traded under the ticker OXOA.STU.
When is the next Oxford Biomedica earnings date?▼
Oxford Biomedica is going to release the next earnings report on September 23, 2026.
What were Oxford Biomedica earnings last quarter?▼
OXOA.STU earnings for the last quarter are -0.06 EUR per share, whereas the estimation was -0.09 EUR resulting in a +31.99% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Oxford Biomedica have?▼
As of April 11, 2026, the company has 977 employees.
In which sector is Oxford Biomedica located?▼
Oxford Biomedica operates in the Health & Wellness sector.
When did Oxford Biomedica complete a stock split?▼
Oxford Biomedica has not had any recent stock splits.
Where is Oxford Biomedica headquartered?▼
Oxford Biomedica is headquartered in Oxford, United Kingdom.